RxDoctor Payments Data

Robert Gries, MD

Geriatric Medicine · Honolulu, HINPI 1669425906

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 45.2% of the total. Reporting peaked in 2022 at $177 and has fallen 60.9% since, to $69 in 2025.

$576in general payments, 2019–2025

Across 24 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$261
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$140
  • Avanir Pharmaceuticals, Inc.$93
  • Biogen$83

What the payments were for

  • Food & beverage$52892%
  • Education$498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$576 in reported general payments places this provider in the 85th percentile of 55 geriatric medicine providers in Hawaii.

See all geriatric medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$599,253
Medicare patients
1,163
Services billed
11,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban842$397,300
JanuviaSitagliptin Phosphate364$186,144
JardianceEmpagliflozin126$68,531
Sevelamer Carbonate118$50,347
Invega SustennaPaliperidone Palmitate19$49,725
BrilintaTicagrelor134$48,574
Esomeprazole Magnesium233$43,853
TradjentaLinagliptin84$41,997
XareltoRivaroxaban94$41,401
OzempicSemaglutide39$39,817
LokelmaSodium Zirconium Cyclosilicate51$38,875
Abilify MaintenaAripiprazole13$38,656
CaplytaLumateperone Tosylate22$38,601
LinzessLinaclotide61$36,656
DovatoDolutegravir Sodium/Lamivudine11$34,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$140$38,60122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 geriatric medicine providers in Hawaii.

Other geriatric medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →